The Effects of Long-Term Oral Benfotiamine Supplementation on Peripheral Nerve Function and Inflammatory Markers in Patients With Type 1 Diabetes

OBJECTIVE To study the effects of long-term oral benfotiamine supplementation on peripheral nerve function and soluble inflammatory markers in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS The study randomly assigned 67 patients with type 1 diabetes to receive 24-month benfotiamine (300 mg/day) or placebo supplementation. Peripheral nerve function and levels of soluble inflammatory variables were assessed at baseline and at 24 months. RESULTS Fifty-nine patients completed the study. Marked increases in whole-blood concentrations of thiamine and thiamine diphosphate were found in the benfotiamine group (both P < 0.001 vs. placebo). However, no significant differences in changes in peripheral nerve function or soluble inflammatory biomarkers were observed between the groups. CONCLUSIONS Our findings suggest that high-dose benfotiamine (300 mg/day) supplementation over 24 months has no significant effects upon peripheral nerve function or soluble markers of inflammation in patients with type 1 diabetes.

• Publication year

  2012

• Venue

  Diabetes Care

• Publication date

  2012-04-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/dc11-1895PMID 22446172PMCID 3329837
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy.

  2009cited by this paper
• Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study.

  2008cited by this paper
• Benfotiamine relieves inflammatory and neuropathic pain in rats.

  2006cited by this paper
• Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study).

  2005cited by this paper
• Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy

  2003cited by this paper
• Optimal blood glucose control during 18 years preserves peripheral nerve function in patients with 30 years' duration of type 1 diabetes.

  2003cited by this paper
• Symptom scoring systems to diagnose distal polyneuropathy in diabetes: the Diabetic Neuropathy Symptom score

  2002cited by this paper
• Comparative bioavailability of two vitamin B1 preparations: benfotiamine and thiamine mononitrate.

  1997cited by this paper
• A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population

  1993influential reference

• Effects of benfotiamine treatment over 12 months on morphometric, neurophysiological and clinical measures in type 2 diabetes patients with symptomatic polyneuropathy: a randomized, placebo-controlled, double-blind clinical trial (BOND study)

  2026cites this paper
• Diabetic neuropathy: cutting-edge research and future directions

  2025cites this paper
• Unraveling the Systems Biology of Curcumin: A Mini-review of its Anti-diabetic Potential through Network Pharmacology.

  2025cites this paper
• Thiamine as a putative natural modulator of PPARγ: exploring a nutrient-based approach for type 2 diabetes

  2025cites this paper
• Association of transketolase polymorphisms with diabetic polyneuropathy in the general population: The KORA F4 study

  2024cites this paper
• An overview on glycation: molecular mechanisms, impact on proteins, pathogenesis, and inhibition

  2024cites this paper
• Assessment for Diabetic Neuropathy: Treatment and Neurobiological Perspective.

  2024cites this paper
• Effects of dietary supplementation in treatment and control of progression and complications of insulin-dependent diabetes mellitus: a systematic review with meta-analyses of randomized clinical trials

  2024cites this paper
• Thiamine and benfotiamine: Focus on their therapeutic potential

  2023cites this paper
• Cell metabolism pathways involved in the pathophysiological changes of diabetic peripheral neuropathy

  2023cites this paper
• Role of Histone Deacetylase Inhibitor in Diabetic Painful Neuropathy

  2023cites this paper
• Therapeutic potential of vitamin B1 derivative benfotiamine from diabetes to COVID-19.

  2022cites this paper
• Effect of thiamine supplementation on glycaemic outcomes in adults with type 2 diabetes: a systematic review and meta-analysis

  2022cites this paper
• BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy

  2022cites this paper
• A systematic review of the prevalence, risk factors and screening tools for autonomic and diabetic peripheral neuropathy in children, adolescents and young adults with type 1 diabetes

  2022cites this paper
• Vitamin B for treating diabetic peripheral neuropathy - A systematic review.

  2021cites this paper
• B vitamins as a treatment for diabetic pain and neuropathy

  2021cites this paper
• Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy

  2021cites this paper
• Effect of Acupuncture on Diabetic Neuropathy: A Narrative Review

  2021cites this paper
• Targeting the receptor for advanced glycation end products (RAGE) in type 1 diabetes

  2020cites this paper
• Diabetic Peripheral Neuropathy: Diagnosis and Treatment.

  2020cites this paper
• Liver nucleotide biosynthesis is linked to protection from vascular complications in individuals with long-term type 1 diabetes

  2020cites this paper
• The Role of the Pentose Phosphate Pathway in Diabetes and Cancer

  2020cites this paper
• Evolving concepts on the role of dyslipidemia, bioenergetics, and inflammation in the pathogenesis and treatment of diabetic peripheral neuropathy

  2020cites this paper
• Diabetic neuropathy

  2019cites this paper
• Painful diabetic polyneuropathy: from clinical guidelines to daily practice

  2019cites this paper
• Diabetic neuropathy

  2019cites this paper
• Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets

  2018cites this paper
• The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review

  2018cites this paper
• Role of advanced glycation end products in mobility and considerations in possible dietary and nutritional intervention strategies

  2018cites this paper
• Transketolase Activity but not Thiamine Membrane Transport Change in Response to Hyperglycaemia and Kidney Dysfunction.

  2017cites this paper
• Diabetes mellitus as a poor mobilizer condition.

  2017cites this paper
• d-Ribose as a Contributor to Glycated Haemoglobin

  2017cites this paper
• Might genetics play a role in understanding and treating diabetic polyneuropathy?

  2017cites this paper
• Electro-neurophysiological criteria of efficiency of pathogenetic therapy in diabetic polyneuropathy

  2017cites this paper
• Association of transketolase polymorphisms with measures of polyneuropathy in patients with recently diagnosed diabetes

  2017cites this paper
• Declining Skeletal Muscle Function in Diabetic Peripheral Neuropathy.

  2017cites this paper
• The progress in understanding and treatment of diabetic retinopathy.

  2016cites this paper
• Targeting advanced glycation with pharmaceutical agents: where are we now?

  2016cites this paper
• Updates in diabetic peripheral neuropathy

  2016cites this paper
• Pharmacokinetics of the transdermal delivery of benfotiamine

  2016cites this paper
• Is Eosinophilic Esophagitis a Sugar Sensitive Disease

  2016cites this paper
• Chapter 51 – Diabetes and Long-Term Complications

  2016cites this paper
• Basic and Clinical Research Against Advanced Glycation End Products (AGEs): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications.

  2015cites this paper
• Paraptosis Cell Death Induction by the Thiamine Analog Benfotiamine in Leukemia Cells

  2015cites this paper
• Pharmacologic Approaches Against Advanced Glycation End Products (AGEs) in Diabetic Cardiovascular Disease

  2015cites this paper
• Поиск патогенетической терапии диабетической дистальной симметричной полинейропатии

  2015cites this paper
• Evidence for altered thiamine metabolism in diabetes: Is there a potential to oppose gluco- and lipotoxicity by rational supplementation?

  2014cites this paper
• Metabolic Benefits of Six-month Thiamine Supplementation in Patients With and Without Diabetes Mellitus Type 2

  2014cites this paper
• Current options and perspectives in the treatment of diabetic neuropathy.

  2013cites this paper
• Whither pathogenetic treatments for diabetic polyneuropathy?

  2013cites this paper
• Advances in our understanding of diabetic retinopathy.

  2013cites this paper
• Molecular strategies to prevent, inhibit, and degrade advanced glycoxidation and advanced lipoxidation end products

  2013cites this paper
• Comment on: Fraser et al. The Effects of Long-Term Oral Benfotiamine Supplementation on Peripheral Nerve Function and Inflammatory Markers in Patients With Type 1 Diabetes: A 24-Month, Double-Blind, Randomized, Placebo-Controlled Trial. Diabetes Care 2012;35:1095–1097

  2012cites this paper